Evofem Biosciences Appoints Interim Chief Financial Officer
SAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to explore other opportunities.
Mr. Altro brings over 25 years of financial and operational experience including corporate restructuring, public accounting and executive management, and consulting, primarily in a leadership role. His experience spans a variety of industries and organizations, servicing primarily middle market privately held corporations, as well as debtors-in-possession, secured and unsecured creditors, private equity groups and strategic buyers. Prior to forming Traverse LLC in 2005, Mr. Altro worked at KPMG in both the auditing group and the strategic consulting practice; he also was a Director at PricewaterhouseCoopers in the Transaction Services Group and worked as a corporate restructuring advisor at Zolfo Cooper (acquired by Alix Partners).
"We will look to Albert's extensive experience to inform and direct our fiscal strategy as we explore options to build shareholder value," said Saundra Pelletier, Chief Executive Officer of Evofem.
Mr. Altro has served on the boards of directors of The Corporate Presence, Pekay Boutiques, Bumblebee Foods and Paramount Business Solutions. He holds a BA in accounting from Long Beach State, and is a member of the Association of Insolvency and Restructuring Advisors (AIRA) and the Turnaround Management Association (TMA).
Pelletier added, "On behalf of the Board I want to thank Jay for his services and wish him success in his future endeavors."
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-appoints-interim-chief-financial-officer-301767432.html
SOURCE Evofem Biosciences, Inc.
Company Codes: NASDAQ-NMS:EVFM, OTC-BB:EVFM, OTC-QB:EVFM